LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS

被引：3
|
作者：
Sitz, K.
Soong, W.
Lanier, B.
Kobayashi, K.
Barve, A.
Hua, E.
Janocha, R.
Severin, T.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.257
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P153
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results
    Metz, M.
    Greiner, A.
    Guduri, S.
    Leflein, J.
    Haemmerle, S.
    Lheritier, K.
    Walsh, P.
    Nikolaev, I.
    Gimenez-Arnau, A. M.
    Maurer, M.
    ALLERGY, 2023, 78 : 245 - 246
  • [22] Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Bernstein, Jonathan A.
    Chu, Chia-Yu
    Danilycheva, Inna
    Hide, Michihiro
    Makris, Michael
    Metz, Martin
    Savic, Sinisa
    Sitz, Karl
    Soong, Weily
    Staubach, Petra
    Sussman, Gordon
    Barve, Avantika
    Burciu, Alis
    Hua, Eva
    Janocha, Reinhold
    Severin, Thomas
    ALLERGY, 2022, 77 (07) : 2175 - 2184
  • [23] Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
    Maurer, Marcus
    Ensina, Luis Felipe
    Gimenez-Arnau, Ana Maria
    Sussman, Gordon
    Hide, Michihiro
    Saini, Sarbjit
    Grattan, Clive
    Fomina, Daria
    Rigopoulos, Dimitrios
    Berard, Frederic
    Canonica, Giorgio Walter
    Rockmann, Heike
    Irani, Carla
    Szepietowski, Jacek C.
    Leflein, Jeffrey
    Bernstein, Jonathan A.
    Peter, Jonny G.
    Kulthanan, Kanokvalai
    Godse, Kiran
    Ardusso, Ledit
    Ukhanova, Olga
    Staubach, Petra
    Sinclair, Rodney
    Gogate, Shaila
    Thomsen, Simon Francis
    Tanus, Tonny
    Ye, Young Min
    Burciu, Alis
    Barve, Avantika
    Modi, Darshna
    Scosyrev, Emil
    Hua, Eva
    Letzelter, Kerstin
    Varanasi, Vineeth
    Patekar, Manmath
    Severin, Thomas
    LANCET, 2024, 403 (10422): : 147 - 159
  • [24] Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
    Gimenez-Arnau, A. M.
    Hayama, K.
    Jain, V.
    Sitz, K.
    Lheritier, K.
    Nikolaev, I.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ALLERGY, 2023, 78 : 245 - 245
  • [25] Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the phase 2B study
    Maurer, M.
    Gimenez-Arnau, A. M.
    Jain, V.
    Reich, A.
    Ortmann, C. E.
    Walsh, P.
    Haemmerle, S.
    ALLERGY, 2023, 78
  • [26] Dupilumab Reduces Disease Activity in Patients with Chronic Spontaneous Urticaria: LIBERTYCSU CUPID Study A
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Kaplan, Allen
    Saini, Sarbjit
    Ensina, Luis Felipe
    Hide, Michihiro
    Praestgaard, Amy
    Gonzalez, Tayler
    Cyr, Sonya
    Sugerman, Philip
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB10 - AB10
  • [27] Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
    Maurer, Marcus
    Casale, Thomas
    Saini, Sarbjit
    Ben-Shoshan, Moshe
    Amin, Nikhil
    Radin, Allen
    Akinlade, Bolanle
    Fan, Chunpeng
    Bauer, Deborah
    Laws, Elizabeth
    Mannent, Leda
    Stjepanovic, Aleksandra
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB312 - AB312
  • [28] Results of the Eteplirsen Phase 2b and Phase 2b Extension Study in Duchenne Muscular Dystrophy
    Kaye, Ed
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (06) : A13 - A13
  • [29] Long-term treatment with remibrutinib shows favourable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week Phase 2b extension study
    Gimenez-Arnau, A. M.
    Tillinghast, J.
    Jain, V.
    Haemmerle, S.
    Lheritier, K.
    Walsh, P.
    Hugot, S.
    Wells, M.
    Zharkov, A.
    Carr, W.
    ALLERGY, 2023, 78 : 244 - 245
  • [30] Extrafine Single Inhaler Triple Therapy Reduces Use Of Rescue Medication In COPD Patients: Results From The Trinity Study
    Scuri, M.
    Singh, D.
    Papi, A.
    Corradi, M.
    Montagna, I.
    Francisco, C.
    Cohuet, G.
    Vezzoli, S.
    Muraro, A.
    Petruzzelli, S.
    Vestbo, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345